Gastric CancerNCT07072429
Annual Hospital Volume and and Short-term Postoperative Outcomes After Gastric Cancer Resection
An observational study of Gastric Cancer, run by Cantonal Hospital of St. Gallen at 1 site in Switzerland.
Trial summary
The effect of centralisation measures on the operative outcomes after gastric cancer resection in Switzerland has not been highlighted yet. This study aims to investigate the influence of the annual hospital specific case load of gastric cancer resection on short-term postoperative outcomes. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Gastric Cancer
- What is being tested?
- Gastric cancer resection
- Type of treatment
- Surgery or procedure
- How many people
- 3,112 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2013to 1 Mar 2023
- How long will I take part?
- 90 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Adult, Older adult
Study population: All patients with gastric cancer resection in Switzerland between 2013 and 2022.
Who may be able to join
- All patients with gastric cancer resection in Switzerland between 2013 and 2022.
Who cannot join
- incomplete case documentation
- age under 20 years
- other hospitals than general or surgical hospitals
- no index operation
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
HOCH Health Ostschweiz, Kantonsspital St.Gallen
Sankt Gallen, 9000
About this study
Official title: Association of Annual Hospital Volume With Mortality, Reoperation, and Length of Hospital Stay After Gastric Cancer Resection in Switzerland: A Retrospective National Registry Study
The effect of centralisation measures on the operative outcomes after gastric cancer resection in Switzerland has not been highlighted yet. This study aims to investigate the influence of the annual hospital specific case load of gastric cancer resection on short-term postoperative outcomes.
- Conditions
- Gastric Cancer
- Being tested
- Gastric cancer resection
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gastric cancer resectionProcedure or surgery
Any kind of surgical gastric cancer resection
| Study group | Role | What they receive |
|---|---|---|
| Gastric cancer resection | Not described Receives: Procedure: Gastric cancer resection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
The association between the hospital volume and the postoperative mortality of gastric cancer resection as marginal effect with GAM (Generalized Additive Models) logistic regression
Measured: Periprocedural
Secondary outcomes (3)
Reoperation
The association between the hospital volume and the reoperation rate of gastric cancer resection as marginal effect with GAM logistic regression
Measured: Periprocedural
Length of hospital stay
The association between the hospital volume and the length of hospital stay of gastric cancer resection as marginal effect with quantile regression.
Measured: Periprocedural
Sociodemographic trends
Measured: 2013 - 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2025
- Study start1 Jan 2013
- Primary completion31 Dec 2022
- Study completion1 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,112 participants (actual)
- Target duration
- 90 Days
Sponsor and investigators
- Lead sponsor
- Cantonal Hospital of St. Gallen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yanic Ammann, Cantonal Hospital of St. Gallen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07072429
- Sponsor's protocol ID
- Hospital volume GCR
- Status last verified
- Jul 2025
- First submitted
- 9 Jul 2025
- Last updated
- 22 Jul 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Annual Hospital Volume With Mortality, Reoperation, and Length of Hospital Stay After Gastric Cancer Resection in Switzerland: A Retrospective National Registry Study
- ClinicalTrials.gov ID
- NCT07072429
- Acronym / sponsor ID
- Hospital volume GCR
- Conditions
- Gastric Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,112 participants (actual)
- Lead sponsor
- Cantonal Hospital of St. GallenUniversity, hospital or other
- Study start
- 1 Jan 2013 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 1 Mar 2023 (actual)
- First posted
- 18 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The effect of centralisation measures on the operative outcomes after gastric cancer resection in Switzerland has not been highlighted yet. This study aims to investigate the influence of the annual hospital specific case load of gastric cancer resection on short-term postoperative outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 90 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Gastric cancer resection | – | Procedure: Gastric cancer resection |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients with gastric cancer resection in Switzerland between 2013 and 2022.
Key inclusion criteria (1 listed)
- All patients with gastric cancer resection in Switzerland between 2013 and 2022.
Key exclusion criteria (4 listed)
- incomplete case documentation
- age under 20 years
- other hospitals than general or surgical hospitals
- no index operation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gastric cancer resectionAny kind of surgical gastric cancer resection | Procedure or surgery | Gastric cancer resection |
Primary outcome
Mortality
Time frame: Periprocedural
The association between the hospital volume and the postoperative mortality of gastric cancer resection as marginal effect with GAM (Generalized Additive Models) logistic regression
3 secondary outcomes
Reoperation
Time frame: Periprocedural
Length of hospital stay
Time frame: Periprocedural
Sociodemographic trends
Time frame: 2013 - 2022
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancer, run by Cantonal Hospital of St. Gallen at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: Periprocedural). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2025.